6-MeO-RU-28306

6-MeO-RU-28306
Clinical data
Other names6-Methoxy-RU-28306; 6-MeO-RU28306; 6-Methoxy-RU28306; 4,α-Methylene-5-methoxy-N,N-dimethyltryptamine; 4,α-Methylene-5-MeO-DMT
Drug classSerotonin receptor modulator
ATC code
  • None
Identifiers
  • 6-methoxy-N,N-dimethyl-1,3,4,5-tetrahydrobenzo[cd]indol-4-amine
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC14H18N2O
Molar mass230.311 g·mol−1
3D model (JSmol)
  • CN(C)C1CC2=CNC3=C2C(=C(C=C3)OC)C1
  • InChI=1S/C14H18N2O/c1-16(2)10-6-9-8-15-12-4-5-13(17-3)11(7-10)14(9)12/h4-5,8,10,15H,6-7H2,1-3H3
  • Key:ZHSVGDFOQZTIEK-UHFFFAOYSA-N

6-MeO-RU-28306, or 6-methoxy-RU-28306, also known as 4,α-methylene-5-methoxy-N,N-dimethyltryptamine (4,α-methylene-5-MeO-DMT), is a serotonin receptor modulator and a cyclized tryptamine and partial ergoline.[1] It is the 6-methoxy derivative of RU-28306 (4,α-methylene-DMT) and a cyclized derivative of 5-MeO-DMT.[1] The drug showed affinity for the serotonin-labeled serotonin 5-HT1 receptors and spiperone-labeled serotonin 5-HT2 receptors in rat frontal cortex membranes in vitro (IC50Tooltip half-maximal inhibitory concentration = 96 nM and 1,756 nM, respectively).[1] 6-MeO-RU-28306 robustly reduced hypothalamic 5-hydroxyindoleacetic acid (5-HIAA) levels and increased circulating corticosterone levels in rodents in vivo, which are both measures of serotonin receptor agonist activity.[1] The chemical synthesis of 6-MeO-RU-28306 has been described.[1] 6-MeO-RU-28306 was first described in the scientific literature by 1988.[1]

See also

References

  1. ^ a b c d e f Flaugh ME, Mullen DL, Fuller RW, Mason NR (September 1988). "6-substituted 1,3,4,5-tetrahydrobenz[cd]indol-4-amines: potent serotonin agonists". Journal of Medicinal Chemistry. 31 (9): 1746–1753. doi:10.1021/jm00117a013. PMID 2457705.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.